Virtus LifeSci Biotech Clinical Trls ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Virtus LifeSci Biotech Clinical Trials ETF BBC
Morningstar’s Analysis BBC
Will BBC outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the BBC management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of BBC’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 18.8
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Erasca Inc | 3.04 | 1M | Healthcare |
Tango Therapeutics Inc | 2.49 | 999,835 | Healthcare |
Spyre Therapeutics Inc | 1.88 | 753,099 | Healthcare |
Enliven Therapeutics Inc | 1.87 | 750,413 | Healthcare |
Oruka Therapeutics Inc | 1.77 | 711,198 | Healthcare |
Liquidia Corp Ordinary Shares | 1.68 | 672,702 | Healthcare |
Rezolute Inc | 1.68 | 672,269 | Healthcare |
Definium Therapeutics Inc Ordinary Shares | 1.50 | 602,244 | Healthcare |
Revolution Medicines Inc Ordinary Shares | 1.48 | 592,742 | Healthcare |
Alumis Inc | 1.42 | 570,236 | Healthcare |
United States